Johansson Hans-Erik, Haenni Arvo, Ohrvall Margareta, Sundbom Magnus, Zethelius Björn
Department of Public Health and Caring Sciences/Geriatrics, Uppsala University Hospital, Uppsala Science Park, 75185, Uppsala, Sweden.
Obes Surg. 2009 May;19(5):601-7. doi: 10.1007/s11695-009-9806-x. Epub 2009 Feb 20.
Roux-en-Y gastric bypass (RYGBP) powerfully reduces type 2 diabetes (T2DM) incidence. Proinsulin predicts development of T2DM. Adjustable gastric banding is associated with lowered proinsulin but after RYGBP information is scant.
Twenty-one non-diabetic morbidly obese patients who underwent RYGBP surgery were evaluated before (baseline), at 12 months (first follow-up), and at 42 months, range 36-50 (second follow-up), after surgery and compared to a control group, matched at baseline regarding fasting glucose, insulin, proinsulin, alanine aminotransferase (ALT), high-density lipoprotein (HDL) cholesterol, and body mass index (BMI).
In the RYGBP group, fasting serum proinsulin concentrations were markedly lowered from 13.5 to 3.5 pmol/l at first follow-up and to 4.9 pmol/l at second follow-up (p < 0.001, respectively). Fasting insulin concentrations were reduced from 83.4 to 24.6 pmol/l at first follow-up (p < 0.001) and to 36.4 pmol/l at second follow-up (p < 0.01). ALT was lowered from 0.62 to 0.34 mukatal/l at first follow-up and continued to lower to 0.24 mukatal/l at second follow-up (p < 0.001, respectively). The further decrease between first and second follow-up was also significant (p = 0.002). HDL cholesterol increased from 1.16 to 1.45 mmol/l at the first follow-up and continued to increase at second follow-up to 1.58 mmol/l (p < 0.001, respectively). The further increase between first and second follow-up was also significant (p = 0.006). The differences between groups at first follow-up were significant for BMI, proinsulin, insulin, ALT, and HDL cholesterol (p = 0.04-0.001).
RYGBP surgery in morbidly obese patients is not only characterized by markedly and sustained lowered BMI but also lowered concentrations of proinsulin, insulin, and ALT and increased HDL cholesterol.
Roux-en-Y胃旁路术(RYGBP)能显著降低2型糖尿病(T2DM)的发病率。胰岛素原可预测T2DM的发展。可调节胃束带术与胰岛素原水平降低有关,但关于RYGBP术后的相关信息较少。
对21例接受RYGBP手术的非糖尿病肥胖患者在术前(基线)、术后12个月(首次随访)和术后42个月(36 - 50个月,第二次随访)进行评估,并与一个对照组进行比较,该对照组在空腹血糖、胰岛素、胰岛素原、丙氨酸转氨酶(ALT)、高密度脂蛋白(HDL)胆固醇和体重指数(BMI)方面与基线时匹配。
在RYGBP组中,空腹血清胰岛素原浓度在首次随访时从13.5 pmol/l显著降至3.5 pmol/l,在第二次随访时降至4.9 pmol/l(分别为p < 0.001)。空腹胰岛素浓度在首次随访时从83.4 pmol/l降至24.6 pmol/l(p < 0.001),在第二次随访时降至36.4 pmol/l(p < 0.01)。ALT在首次随访时从0.62 mukatal/l降至0.34 mukatal/l,并在第二次随访时继续降至0.24 mukatal/l(分别为p < 0.001)。首次和第二次随访之间的进一步下降也具有显著性(p = 0.002)。HDL胆固醇在首次随访时从1.16 mmol/l升至1.45 mmol/l,并在第二次随访时继续升至1.58 mmol/l(分别为p < 0.001)。首次和第二次随访之间的进一步升高也具有显著性(p = 0.006)。首次随访时两组在BMI、胰岛素原、胰岛素、ALT和HDL胆固醇方面的差异具有显著性(p = 0.04 - 0.001)。
肥胖患者接受RYGBP手术不仅表现为BMI显著且持续降低,还表现为胰岛素原、胰岛素和ALT浓度降低以及HDL胆固醇升高。